European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Prep: Cook: Serves:

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Last Month

Next Month

Go Back

Share this story

Comments

Europe

Copenhagen carnival: campaigners and cyclists join forces for Unity Walk

Copenhagen’s streets to be overrun with Parkinson’s campaigners

“The darker aspects of Parkinson’s are rarely discussed”

An “open, ruthlessly honest and gritty” film series

£16,000 a year: the hidden price of Parkinson’s

Research reveals the monetary cost of Parkinson’s for UK families

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

A new study from scientists at the University of Cambridge, UK, has brought researchers “a vital step” closer to discovering the origins of Parkinson’s disease. The research, published in the scientific journal ‘Nature Communications’, offered insights on the protein alpha-synuclein, which clumps together in the neurons of people with Parkinson’s. The study focused on how the protein functions in those without the condition and revealed that it sticks to the inner side of the plasma membrane of nerve cells, but not the outer membrane – an insight that could help in the search for a cure. Lead study author, Dr Giuliana Fusco, said: “This study could unlock more information about this debilitating neurodegenerative disorder that can leave people unable to walk and talk. If we want to cure Parkinson’s, first we need to understand the function of alpha-synuclein, a protein present in everyone’s brains.”

Could a prostate drug lower the risk of Parkinson’s disease?

Researchers in the US, Denmark and China have found that a type of medication used to treat enlarged prostate, known as alpha-blockers, is associated with a lower risk of Parkinson’s disease. As part of the study, the research team analysed patient data from 150,000 men using medications like the alpha-blocker terazosin – which has previously been shown to slow Parkinson’s disease progression in animals – and compared their findings to data from 150,000 men using the alpha-blocker tamsulosin. They found that men taking terazosin were 12 to 37% less likely to develop Parkinson’s disease. Jacob Simmering, corresponding author of the study, said: “Despite the relative differences in population and health care system structure, we found a similar protective effect in both [the US and Denmark]. “If these results are confirmed through further investigation, especially a randomised clinical trial, terazosin may provide neuroprotection and potentially prevent – and not just manage…

People with Parkinson’s disease have a “high interest” in herbal drugs, study finds

Researchers in Germany conducted a survey to assess how people with Parkinson’s disease perceive and experience medical cannabis. As part of the study, the team analysed answers from more than 1,300 people with Parkinson’s. They found that 65% of participants who did not use medical cannabis were interested in it, but lacked knowledge and feared side effects. Around 8% of participants reported using cannabis; of these, 54% reported beneficial effects – including 40% who reported reduced pain. Professor Dr Carsten Buhmann, lead study investigator, said: “Our data confirm that Parkinson’s disease patients have a high interest in treatment with medicinal cannabis […]. The data reported here may help physicians decide which patients could benefit, which symptoms could be addressed, and which type of cannabinoid and route of administration might be suitable. “It has to be stressed, though, that our findings are based on subjective patient reports and that clinically appropriate…

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Europe

Copenhagen carnival: campaigners and cyclists join forces for Unity Walk

Interviews

“The darker aspects of Parkinson’s are rarely discussed”

Special reports

£16,000 a year: the hidden price of Parkinson’s

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

Could a prostate drug lower the risk of Parkinson’s disease?

People with Parkinson’s disease have a “high interest” in herbal drugs, study finds

{title}

Subscribe

European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Europe

Copenhagen carnival: campaigners and cyclists join forces for Unity Walk

Interviews

“The darker aspects of Parkinson’s are rarely discussed”

Special reports

£16,000 a year: the hidden price of Parkinson’s

New study brings scientists a “vital step” closer to understanding Parkinson’s disease

Could a prostate drug lower the risk of Parkinson’s disease?

People with Parkinson’s disease have a “high interest” in herbal drugs, study finds

{title}

Subscribe

Sign in